Integrated layout accelerated Two subsidiaries of Weixin Kang obtain B certificate for drug production

On August 18, 2021, Beijing Jingweixinkang Pharmaceutical Technology Development Co.,Ltd.

Development Co., Ltd, a wholly-owned subsidiary of the Company, received the Drug Production License (Bh) issued by Beijing Municipal Drug Administration, approving Jingwei Xinkang's qualification as a pharmaceutical marketing license holder and agreeing to Inner Mongolia Baiyi Pharmaceutical Co., Ltd. It became an important milestone for the company to actively lay out the integration of research, production and marketing.

In November, the Drug Manufacturing License (Bh) applied for by Yangpu Jingtai Pharmaceutical Co.,Ltd., a subsidiary of the Company, was approved by the Hainan Provincial Drug Administration, which approved Yangpu Jingtai's qualification as a holder of the drug marketing license and agreed to Inner Mongolia Baiyi Pharmaceutical Co., Ltd. 

The acquisition of the Drug Manufacturing License (Bh) indicates that the Company has qualified as a holder of a drug marketing license and can apply for a marketing license as a holder of a drug manufacturing approval for the Company's products under research, products in production or other means through the relevant reporting procedures.

The MAH system allows R&D institutions, natural persons and other entities that are not qualified to manufacture drugs to obtain marketing authorisation through collaboration or consignment. This effectively protects their R&D incentives and helps to reduce duplication of construction and improve capacity utilisation.